Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III perioperative durvalumab plus chemotherapy versus placebo plus chemotherapy in resectable stage II-III non-small cell lung cancer
jRCT2080224587Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Perioperative durvalumab arm with Perioperative placebo arm (2 arms). Started Mar 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224587.